My Recent Searches
- No Recent Search.
My Tests Viewed
- No Test Viewed.
RET/PTC Rearrangement, Thyroid Cancer
Real-Time Polymerase Chain Reaction (PCR)
RET/PTC gene fusion is detected in 5-40% of papillary thyroid carcinomas, but has been reported at low frequency in other types of thyroid lesions. Correlation with morphologic and clinical findings is thus required. The assay tests for both RET/PTC1 and RET/PTC3 rearrangements using a reverse transcription PCR assay. The lower limit of sensitivity is approximately 2.5% mutation-bearing cells in a mixed sample, but can vary due to RNA preservation.
Papillary Thyroid Cancer
To view specimen requirements and codes please Select a regional laboratory.
Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)
Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.